Veraxa Biotech is trading 8.89% up at $1.47, following several consecutive declines.
- Closing price fell from $1.95 to $1.35 between August 21–31.
- No clear company-specific announcement dated September 1, 2026, or August 31, 2026, was identified.
- Its investor-relations page lists an August 24 antibody-oligonucleotide conjugate research milestone, but does not link it to today’s move.